<DOC>
	<DOCNO>NCT02159469</DOCNO>
	<brief_summary>Evaluation efficacy safety testosterone enanthate administer subcutaneously use auto-injector</brief_summary>
	<brief_title>Subcutaneous Testosterone Replacement Efficacy Safety Adult Men Diagnosed With Hypogonadism</brief_title>
	<detailed_description>This study evaluate testosterone enanthate administer subcutaneously week auto injector men low testosterone raise level normal range . The study investigate ability adjust testosterone enanthate dose level use single point blood concentration . Safety tolerability testosterone administration evaluate along patient 's ability use auto injector follow instruction auto injector use . Patient satisfaction sexual functioning also assess 52 week study .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Adult male age ≥ 18 year age document diagnosis hypogonadism Total testosterone level &lt; 300 ng/dL two qualification visit Patients good general health Allergy sesame testosterone product BMI ≥ 40 kg/m2 Hematocrit ≥ 52 % History current evidence breast prostate cancer Elevated PSA age . Abnormal DRE Obstructive uropathy prostatic origin Poorly control diabetes Congestive heart failure Within 6 month screen , MI , unstable angina lead hospitalization , percutaneous coronary intervention , coronary artery bypass graft , uncontrolled cardiac arrhythmia , stroke transient ischemia attack , ceratoid revascularization , endovascular procedure , surgical intervention peripheral vascular disease . History current treatment thromboembolic disease . Use ACTH oral/depot corticosteroid within 6 week screen . History severe , untreated sleep apnea Subjects clinically significant medical condition , opinion investigator , would make subject unsuitable candidate enrollment study Positive serology HIV , hepatitis B hepatitis C Current evidence drug alcohol abuse . Skin condition injection site could confound injection site assessment . Administration investigational compound within one month screen 5 halflives investigational compound , whichever long ) . Use estrogen , GnRH growth hormone within 12 month screen . Use androgen ( DHEA , anabolic steroid , sex hormone ) substances/supplements know affect PK testosterone enanthate Considered schedule surgical dental procedure associate blood loss ≥500 mL study . Donation plasma blood within 56 day screen history donation &gt; 50 mL blood plasma within 3 month screen . Donation plasma blood study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone enanthate</keyword>
</DOC>